Use of Adjuvant Endocrine Therapy Among Post-Menopausal Breast Cancer Patients in Malaysia

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Azizah AM, Hashimah B, Nirmal K, et al. Malaysian National Cancer Report (MNCR) 2012–2016. Malaysia: Ministry of Health; 2019. Available from: https://drive.google.com/file/d/1BuPWrb05N2Jez6sEP8VM5r6JtJtlPN5W/view. Accessed January 21, 2021.
   Google Scholar
• Malaysia clinical practice guidelines: management of breast cancer. Malaysia: Ministry of Health; 2010. Available from: https://www.moh.gov.my/moh/attachments/6915.pdf. Accessed January 21, 2021.
   Google Scholar
• Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–438. doi:10.1200/JCO.18.01160
   PubMed Web of Science ®Google Scholar
• van Hellemond IEG, Geurts SME, Tjan-Heijnen VCG. Current status of extended adjuvant endocrine therapy in early stage breast cancer. Curr Treat Options Oncol. 2018;19(5):26. doi:10.1007/s11864-018-0541-1
   Web of Science ®Google Scholar
• Choo SB, Saifulbahri A, Zullkifli SN, et al. Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia. Climacteric. 2019;22(2):175–181. doi:10.1080/13697137.2018.1540563
   PubMedGoogle Scholar
• Calip GS, Xing S, Jun D-H, et al. Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer. J Oncol Pract. 2017;13(5):e451–e462. doi:10.1200/JOP.2016.018317
   Web of Science ®Google Scholar
• Brett J, Fenlon D, Boulton M, et al. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care (Engl). 2018;27(1):e12601. doi:10.1111/ecc.12601.
   Web of Science ®Google Scholar
• Lambert LK, Balneaves LG, Howard AF, et al. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat. 2018;167(3):615–633. doi:10.1007/s10549-017-4561-5
   Web of Science ®Google Scholar
• Farias AJ, Du XL. Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer. J Clin Oncol. 2017;35(1):86–95. doi:10.1200/JCO.2016.68.2807
   Web of Science ®Google Scholar
• Ali EE, Cheung KL, Lee CP, et al. Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore. Asia Pac J Oncol Nurs. 2017;4(4):283–289. doi:10.4103/2347-5625.212864
   Web of Science ®Google Scholar
• Quinn EM, Fleming C, O’Sullivan MJ. Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy. Ir J Med Sci. 2016;185(2):383–392. doi:10.1007/s11845-015-1307-4
   Web of Science ®Google Scholar
• Pieters HC, Green E, Khakshooy S, et al. A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy. PLoS One. 2019;14(1):e0210972. doi:10.1371/journal.pone.0210972
   Web of Science ®Google Scholar
• Moon Z, Moss-Morris R, Hunter MS, et al. Understanding tamoxifen adherence in women with breast cancer: a qualitative study. Br J Health Psychol. 2017;22(4):978–997. doi:10.1111/bjhp.12266
   PubMed Web of Science ®Google Scholar
• Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82. doi:10.1177/1525822X05279903
   Web of Science ®Google Scholar
• Vaismoradi M, Jones J, Turunen H, et al. Theme development in qualitative content analysis and thematic analysis. J Nurs Educ Pract. 2016;6(5):100–110.
   Google Scholar
• Li L, Chang B, Jiang X, et al. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer. 2018;18(1):977. doi:10.1186/s12885-018-4878-4
   Web of Science ®Google Scholar
• Horne R, Chapman SC, Parham R, et al. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One. 2013;8(12):e80633. doi:10.1371/journal.pone.0080633
   PubMed Web of Science ®Google Scholar
• Nies YH, Islahudin F, Chong WW, et al. Treatment decision-making among breast cancer patients in Malaysia. Patient Prefer Adherence. 2017;11:1767–1777. doi:10.2147/PPA.S143611
   Web of Science ®Google Scholar
• Lim WY, Hss AS, Ng LM, et al. The impact of a prescription review and prescriber feedback system on prescribing practices in primary care clinics: a cluster randomised trial. BMC Fam Pract. 2018;19(1):120. doi:10.1186/s12875-018-0808-4
   PubMed Web of Science ®Google Scholar
• Department of statistic Malaysia, current population estimates, Malaysia, 2018–2019. Available from: https://www.dosm.gov.my/v1/index.php?r=column/cthemeByCat&cat=155&bul_id=aWJZRkJ4UEdKcUZpT2tVT090Snpydz09&menu_id=L0pheU43NWJwRWVSZklWdzQ4TlhUUT09#:~:text=Malaysia’s%20population%20in%202019%20is,1.1%20per%20cent%20in%202018. Accessed January 21, 2021.
   Google Scholar
• Mohd Mujar NM, Dahlui M, Emran NA, et al. Complementary and alternative medicine (CAM) use and delays in presentation and diagnosis of breast cancer patients in public hospitals in Malaysia. PLoS One. 2017;12(4):e0176394. doi:10.1371/journal.pone.0176394
   Web of Science ®Google Scholar
• Farrukh MJ, Makmor-Bakry M, Hatah E, et al. Use of complementary and alternative medicine and adherence to antiepileptic drug therapy among epilepsy patients: a systematic review. Patient Prefer Adherence. 2018;12:2111–2121. doi:10.2147/PPA.S179031
   PubMed Web of Science ®Google Scholar
• Lew YL, Ismail F, Abdul Aziz SA, et al. Information received and usefulness of the sources of information to cancer patients at a tertiary care centre in Malaysia. J Cancer Educ. 2019. doi:10.1007/s13187-019-01637-9
   Web of Science ®Google Scholar
• Heisig SR, Shedden-Mora MC, von Blanckenburg P, et al. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Psychooncology. 2015;24(2):130–137. doi:10.1002/pon.3611
   Web of Science ®Google Scholar
• Härter M, Moumjid N, Cornuz J, et al. Shared decision making in 2017: international accomplishments in policy, research and implementation. Z Evid Fortbild Qual Gesundhwes. 2017;123:1–5. doi:10.1016/j.zefq.2017.05.024
   PubMed Web of Science ®Google Scholar
• Latenstein CSS, Thunnissen FM, Thomeer BJM, et al. The association between patients’ preferred treatment after the use of a patient decision aid and their choice of eventual treatment. Health Expect. 2020;23(3):651–658.
   Web of Science ®Google Scholar
• Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.
   PubMed Web of Science ®Google Scholar